>These safety vs. efficacy results make me wonder if Apixaban's dose wasn't too low.<
You could be right. The Apixaban doses being tested in phase-3 for VTE treatment (as opposed to VTE prevention) are higher than the 2.5mg BID dose in the failed ADVANCE-1 trial. For instance, the AMPLIFY trial uses a loading dose of 10mg BID followed by a maintenance dose of 5mg BID (#msg-29928836).
Moreover, the phase-2 trial of Apixaban vs warfarin in VTE prevention employed doses of 5mg BID, 10mg BID, and 20mg qD (#msg-21044973).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.